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Abstract
Many targets have been identified in solid tumors for antibody therapy but it is less clear what
surface antigens may be most commonly expressed on disseminated tumor cells. Using malignant
pleural effusions as a source of disseminated tumor cells, we compared a panel of 35 antigens for
their cancer specificity, antigen abundance and functional significance. These antigens have been
previously implicated in cancer metastasis and fall into four categories: (i) cancer stem cell, (ii)
epithelial-mesenchymal transition, (iii) metastatic signature of in vivo selection and (iv) tyrosine
kinase receptors. We determined the antigen density of all 35 antigens on the cell surface by flow
cytometry, which ranges from 3 × 103−7 3 106 copies per cell. Comparison between the malignant
and benign pleural effusions enabled us to determine the antigens specific for cancer. We further
chose six antigens and examined the correlation between their expression levels and tumor
formation in immunocompromised mice. We concluded that CD24 is one of the few antigens that
could simultaneously meet all three criteria of an ideal target. It was specifically and abundantly
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expressed in malignant pleural effusions; CD24high tumor cells formed tumors in mice at a faster
rate than CD24low tumor cells, and shRNA-mediated knockdown of CD24 in HT29 cells
confirmed a functional requirement for CD24 in the colonization of the lung. Concomitant
consideration of antigen abundance, specificity and functional importance can help identify
potentially useful markers for disseminated tumor cells.
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The discovery and validation of antigen targets is the first step in the development of an
efficacious antibody therapy.1 Several successful targets have been identified in solid
tumors, but it is unclear whether the same targets are equally applicable to disseminated
tumor cells, which are detached from the primary site and often possess greater tumorigenic
potential than cells in the primary tumor.2 We wished to evaluate a panel of antigens for
their suitability to target disseminated tumor cells.
In terms of antigen characterization, an ideal antibody target should fulfill three criteria: (i)
cancer specificity, (ii) abundant expression and (iii) functional importance.1 One of the most
successful antibody targets, ErbB2, is an antigen that meets all three criteria. ErbB2 is
overexpressed in 82% of breast cancer samples.3 However, antibody therapy against ErbB2
with Trastuzumab is only effective in patients expressing the highest levels of ErbB2 at
around 5 × 105 receptors per cell but ineffective in patients expressing 2 × 105 receptors per
cell, indicating that abundant expression of the antigen is an essential determinant of
therapeutic outcome.4 Functionally, ErbB2 plays an important role in tumor growth as it can
activate survival and mitogenic pathways.5
Although many targets have been evaluated according to the aforementioned guidelines in
solid tumors, few antigens have been assessed in disseminated tumor cells. On the basis of
recent evidence, we identified candidate antigens that are particularly involved in the
molecular pathways and cellular mechanisms of metastasis. They fall under four general
categories. First, cancer stem cell (CSC) markers have been shown to delineate
subpopulations with markedly increased tumor-initiating potential.6,7 Second, the loss of
epithelial markers and the gain of mesenchymal markers during epithelial-mesenchymal
transition (EMT) are features of a more invasive cell type.8 Third, in vivo selection
experiments have identified gene signatures responsible for the organ tropism of metastasis9
or metastasis in general.10 The fourth class is the family of receptor tyrosine kinases
important for tumor growth, and monoclonal antibodies targeting these are used to treat
solid tumors.11
What’s new?
In order to develop effective antibody therapies, researchers must first identify
cancer-specific antigens that are important for tumor growth or metastasis. Because
few such antigens have been assessed in disseminated tumor cells, the authors
examined a broad panel of surface markers on cells from malignant pleural
effusions. They found that CD24 has three qualities that make it a promising target:
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specificity, abundance, and functional importance for tumorigenesis. CD24 may
thus be well suited to both diagnosis of circulating tumor cells and therapeutic
targeting.
Acquisition of biological materials presents a challenge for target discovery in disseminated
tumor cells1. Circulating tumor cells are too rare (~1 cell/ml blood) for direct screening of
surface antigens12. In contrast, malignant pleural effusions are a large reservoir of highly
malignant tumor cells in suspension (104 −106 cells/L), and with higher tumorigenic
potential than that of primary tumors2. In addition to cancer, congestive heart, renal and liver
diseases can also cause the buildup of fluids in the pleural cavity, forming benign effusions
that can be used as negative controls in the measurement of cancer specificity. Soluble
factors have been evaluated as tumor markers for malignant pleural effusion13,14 but to our
knowledge there has not been a previous screening effort of cell-surface antigens. Cell-
surface antigens are desirable for antibody targeting because they are directly accessible and
localized to the cells of interest.
We evaluated a panel of 35 surface antigens in 12 malignant and 8 benign pleural effusions.
We determined the average receptor number per cell for each of the 35 antigens using flow
cytometry, and validated the tumorigenicity of six targets using tumor formation studies in
immunocompromised mice. We identified CD24 as a potential target for malignant pleural
effusion because it satisfied all three criteria of an ideal antibody target-it is preferentially
expressed in malignant but not in benign pleural effusion; it is abundantly expressed at 6.8 ×
105 receptors/cell and is functionally required for the colonization of the lung by HT29 cells.
Material and Methods
Collection of patient samples
Pleural effusions were obtained from consenting patients as part of an Institutional Review
Board-approved protocol at the Lahey Clinic and Use of Humans as Experimental Subjects-
approved study at MIT. Samples were collected from patients with biopsy-proven cancer
and patients with no cancer as determined by clinical presentation and histology. A total of
400 ml of pleural fluid was set aside for routine cytologic evaluation and the rest was sent to
MIT on ice within 24 hr after collection, and analyzed for surface expression within 48 hr
after collection. A total of 12 malignant pleural effusions and 8 benign effusions were used
for surface antigen analysis. Refer to Supporting Information Table S1 for detailed patient
information.
Surface marker expression analysis using flow cytometry
A total of 30 ml of pleural effusions were passed through a 40 µm cell strainer (BD
Biosciences), incubated with human FcR block (eBioscience) in 1:20 dilution and then
stained with antibodies (see Supporting Information experimental procedures) for 30 min on
ice. DAPI is added immediately before flow cytometry analysis to gate out the dead cells.
Cells were analyzed on LSRII flow cytometer (BD Biosciences) with four different lasers
(355 nm, 488 nm, 561 nm, and 635 nm) in five different channels: DAPI, FITC (marker 1),
PE (marker 2), EpCAM-APC and CD45-PECY7 using HTS plate reader (Supporting
Information Fig. S2B). Antibodies were purchased directly conjugated, or labeled with
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Alexa Fluor 488 dye (Invitrogen) or PE (Dojindo). The fluorophores were chosen to be
those with minimal bleed through. Compensations were performed with beads (Bangs
Laboratory) coated with individual clone of antibodies, and the compensation matrix was
applied to all the patient samples.
Quantification of surface receptors expression
The number of receptors per cell is determined by calibrating the fluorescence intensity
using microspheres with known Antibody Binding Capacities (Bangs Laboratory). The
Quantum Simply Cellular micropheres come with one blank and four standards with
increasing levels of Fc-specific capture antibodies. The beads were labeled to saturation with
the same antibodies used to stain the cells and analyzed on the flow cytometer with the same
settings used to analyze the cells. The standards were then used to construct a calibration
curve (Supporting Information Fig. S2A). The number of antigen was determined by
converting the mean fluorescence level to antibody binding capacities. As we only used
monoclonal antibodies to stain the cells (except cadherin-11), each antibody only binds to
one antigen and the antibody binding capacities of the microspheres is equivalent to the
number of antigens. The mean fluorescence level is tabulated by Flowjo (Tree Star) and
compiled using a Matlab (Mathworks) program. Monoclonal antibody for Cadherin-11 was
not commercially available, so we used a goat polyclonal antibody. The calibration kit
against goat Fc was also not available, so we estimated the number of Cadherin-11 based on
the fluorescence intensity of N-cadherin antibody.
Sorting and animal studies
All experimental protocols were approved by the Animal Care and Use Committee of MIT.
Tumor from patient LC52’s pleural effusion was formed after injecting the cells pelleted
from 30 ml of pleural effusion subcutaneously into NOD/SCID/IL2γR−/− with 200 µl
Matrigel (BD Biosciences). LC52 was propagated in vivo by serial transplantation. The
tumors were cut up with razor blades, and digested in 1 mg/ ml collagenase A (Roche) and
100 units/ml DNAse I (Roche) in RMPI at 37°C for 20 min. Single cell suspensions were
stained with antibodies for 30 min on ice and sorted on Aria (BD) by fluorescence-activated
cell sorting (FACS). Sorted cells were injected with Matrigel and observed for tumor
formation for up to 1 year.
Cell lines and shRNA knockdown
HT29 cells (ATCC) were maintained in DMEM (Cellgro) and 10% FBS (PAA
Laboratories). shRNA lentiviral particles were purchased from Sigma-Aldrich (clone1-
TRCN0000057 675, 5′-CCGG-TCTTCTGCATCTCTACTCTTA-CTCGAG-
TAAGAGTAGAGATGCAGAAGA-TTTTTG-3′ and clone 2-TRCN000007677, 5Ȳ-
CCGG-CGCAGATTTATTCCAGTGAA A-CTCGAG-TTTCACTGGAATAAATCTGCG-
TTTTTG-3′). The nontargeted control uses an shRNA sequence targeting no known
mammalian genes (Sigma-Aldrich SHC002V). Cells were plated at 1 × 104/well in a 96-well
plate, transduced with lentiviral particles, and selected with puromycin for 10 days. After
antibiotic selection, cells were further FACS-sorted for CD24 low-expressing cells.
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Lung colonization study
About 1 × 105 HT29 cells, either transduced with nontargeted shRNA or CD24 shRNA,
were injected into mice through the tail vein. The lung tissue was fixed with 4%
paraformaldehyde for 15 min and rinsed with PBS. The lungs were embedded in paraffin,
sectioned 100 µm apart and stained by hematoxylin and eosin (H&E). The number of
metastases observed was counted and averaged over five sections per mouse.
Statistical analysis
ANOVA tests in Matlab were used to determine p-values of the heatmap. Kaplan-Meier
plots were created and p-value calculated by a log-rank test in GraphPad Prism.
Sample size determination for statistical powering of Type II error is computed by this
formula:
where n = sample size, d = effect or the difference between the means of two populations, s
= standard deviation and C = 7.85 when significance level (α) = 0.05 and power (1–β) =
0.08.
Results
Only the EpCAM+ population of cells in pleural effusions is tumorigenic
The pleural effusion is a complex mixture of immune cells, mesothelial cells, fibroblasts,
and cancer cells. As the proportion of stromal cells can be >90% of the total population,
taking the global average across different cell types would skew the result toward the more
abundant cell types and preclude antigen discovery in rare tumor-forming cells. Therefore,
we used lineage markers—CD45 for hematopoietic cells and EpCAM for epithelial cells—
to provisionally separate the pleural effusions into different subsets. We observed three
distinct populations in malignant pleural effusions: (i) EpCAM+, (ii) EpCAM− /CD45− and
(iii) CD45+ (Fig. 1a). The subsets were morphologically distinct, with the EpCAM+ cells
being round and the EpCAM−/CD45− cells spindle-shaped (Supporting Information Fig.
S1A). The EpCAM+ subset was present in 50% of the malignant pleural effusions and was
completely absent in the benign effusions (Fig. 1a).
Before we could evaluate the antigens for cancer specificity, we need to establish which
subset is tumorigenic. Therefore, we FACS sorted seven malignant effusions into EpCAM+ ,
EpCAM−/CD45− and CD45+ subsets and injected the sorted cells subcutaneously into NOD/
SCID/IL2γR−/− mice, monitoring for tumor growth for up to a year. The sorting results
showed that only the EpCAM+ subset formed tumors in mice, with a 75% efficiency
(Supporting Information Fig. 1b). Four of the seven effusions sorted contained EpCAM+
cells and tumor formation was restricted to these EpCAM+ samples. No tumor formation
was observed with the EpCAM−/CD45− subset (Fig. 1b). All cells obtained from sorting
were injected without normalization to a common cell number, to maximize each subset’s
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probability of tumor formation (Refer to Supporting Information Table S2 for numbers of
cells injected). When pleural effusions were injected into mice without prior sorting, the
formed tumors were entirely EpCAM+ (Fig. 1c). For example, the percentage of EpCAM+
cells in the LC52 sample (Refer Supporting Information Fig. S1B for histology of LC52)
increased from 0.4% to 99% during tumor growth.
CD24 is one of the several surface markers abundantly expressed in malignant pleural
effusions
After establishing that the EpCAM+ subset is tumorigenic, we proceeded to screen surface
antigens for their abundance and cancer specificity. We analyzed 12 malignant and 8 benign
pleural effusions using flow cytometry (Supporting Information Table S1) and stained the
effusions with 35 directly conjugated antibodies. Because the antibodies were labeled with
different fluorophores and with different labeling efficiency, we calibrated the raw
fluorescence signal to the absolute number of surface receptor molecules using beads with
predetermined antibody binding capability (Supporting Information Fig. S2A and Table S3).
We used monoclonal antibodies to calibrate the absolute number of receptors because each
monoclonal antibody should theoretically bind to a single receptor, allowing us to equate the
number of receptors to the number of monoclonal antibodies, with the assumption that all
the receptors are fully saturated with antibodies. Polyclonal antibodies are not suitable for
this application because multiple polyclonal antibodies may bind to a single receptor, thus
overestimating the number of receptors. We included carcinomas of various tissue types
including lung, endometrial or colorectal so as to identify ubiquitously expressed markers.
The benign effusions came from patients with congestive heart failure or liver diseases.
Expression levels of 35 surface markers for each of the five cell subsets described in Figure
1a (malignant EpCAM+, EpCAM−/CD45− and CD45+; benign EpCAM−/CD45− and
CD45+) (Refer Supporting Information Fig. S2B for gating strategy) is shown in the
heatmap (Fig. 2a), which was obtained by averaging all the patient samples for each of the
subsets (Refer to Supporting Information Fig. S2C for individual patient surface antigen
expression). An analysis of variance (ANOVA) was applied to each marker and a small p-
value indicates significant deviation of any one subset from others (most commonly the
cancer patient EpCAM+ subset). A preferred cancer marker was defined as one that is both
consistently overexpressed across multiple cancer patients and found abundantly on the cell
surface (Fig. 2b).
Epithelial markers such as EpCAM, CEA and E-cadherin (E-cad) were among the most
highly expressed surface proteins (Figs. 2a and 2b), at close to 1 × 106 receptors/cell in the
EpCAM+ subset. In contrast, we did not observe high expression of mesenchymal markers
such as N-cadherin (N-cad) and cadherin-11 (Cad-11) in any of the subsets. These
mesenchymal markers were expressed at 1 × 103−1 × 104 receptors/cell, approaching
background staining. The mesenchymal marker FGFR2c was sometimes overexpressed, but
its expression was inconsistent across different patient samples. The expression of signaling
receptors predominantly fell between 1 × 104 and 2 × 105 receptors/cell. ErbB2, ErbB3,
IGF-I Ra were significantly overexpressed in the EpCAM+ subset although they were much
less abundant than the epithelial markers. Integrin αvβ3, SPARC and ICAM1 were the
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adhesion molecules overexpressed in the EpCAM+ subset. Interestingly, CD44 variants and
CD24 but not CD44 were significantly overexpressed in the EpCAM+ subset.
We also compared the marker expression of the EpCAM−/CD45− and CD45+ subsets
between the malignant and benign effusions by t-test. There was no significant difference
between cancer and non-cancer EpCAM−/CD45− cells. However, the CD45+ cells of cancer
samples showed a somewhat higher expression of signaling receptors, namely ErbB2, ErbB3
and IGF-1Ra (Supporting Information Table S4).
CD24 predicts increased tumor growth in xenograft tumors of pleural effusions
We further explored whether antigens overexpressed in the EpCAM+ population were
correlated with tumor growth. To address this question, tumor cells propagated in mice from
the pleural effusion of a colorectal cancer patient (LC52) were sorted based on surface
marker expression. This xenograft tumor was used because it retained the complex tissue
morphology of its origin (Supporting Information Fig. S1B), and could be propagated in the
shortest amount of time (around 2 months for each passage) and could grow to a reasonable
size yielding sufficient cells for subsequent experiments. A total of six antigens
overexpressed in malignant pleural effusions and representing the major categories of
surface antigens were screened for their ability to predict tumorigenesis: CEA (epithelial
marker), ICAM1 (adhesion marker), CD44v7 and CD24 (stem cell markers), and
Cadherin-11 and FGFR2c (mesenchymal markers). After gating on the human cells with
human leukocyte antigen class I (HLA-A, B, C) staining, LC52 tumor cells were sorted into
the top and bottom 10% expressing each of the six antigens (Fig. 3a), reinjected
subcutaneously into NOD/SCID/IL2γR−/− mice, and monitored for tumor growth (Fig. 3b).
CD24high, CEAhigh, CD44v7low, and Cadherin-11low populations formed statistically
significantly faster-growing tumors. The faster tumor growth observed with cell populations
expressing low levels of certain cancer markers suggests that overexpression does not
always correlate with faster tumor growth.
To investigate whether tumors retained the same level of surface expression as their starting
population, we compared the marker expression in tumors formed from high and low
populations by flow cytometry at the end of the tumor induction study (Fig. 3c). Of note,
tumors from CD24low and CEAlow cells regained their CD24 and CEA expression, reaching
the same level of expression as CD24high and CEAhigh tumors. This implies that marker
expression is a dynamic process and that selected markers, in this case CD24 and CEA, are
upregulated as tumors form.
CD24 is critical for tumorigenic lung colonization
To investigate a possible causal role for CD24 in tumorigenicity, we knocked down CD24
expression by shRNA in the HT29 colorectal adenocarcinoma line (Figs. 4a and 4b). A
colorectal line was chosen because LC52 was of rectal origin but LC52 tumor cells were
refractory to lentiviral transduction. HT29 was chosen because it has a marker expression
profile similar to LC52 and other EpCAM+ pleural effusions (Supporting Information Table
S5); high in EpCAM, CEA and CD24.
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We found that HT29 cells transduced with CD24 shRNA grew at a similar rate in vitro as
did the nontargeted control (Fig. 4c). When HT29 cells were injected subcutaneously, CD24
imparted a small but statistically significant growth advantage to tumors during the linear
phase (p < 0.05) (Fig. 4d). Both the in vitro and in vivo growth curves are consistent with
previous observations (15). Interestingly, whereas CD24high HT29 cells formed numerous
tumor nodules in the lungs of mice when injected intravenously, very few nodules were
observed when CD24 was knocked down. This result demonstrates that CD24 expression by
tumor cells is required for efficient lung colonization (Fig. 4e).
Discussion
Identifying a surface antigen commonly expressed on disseminated tumor cells could help
improve therapeutic outcome in metastatic disease. With that objective, we evaluated 35
previously known cancer antigens based on three criteria: cancer specificity, abundance and
functional requirement for tumor growth. We used malignant pleural effusions as the source
of disseminated tumor cells because tumor cells found in the effusions are highly
tumorigenic and much more abundant than other sources of disseminated tumor cells such as
circulating tumor cells in blood or cytokeratin positive cells in bone marrow aspirates.
CD24 emerged as a candidate antigen that fulfilled all three criteria simultaneously—it is
abundantly and specifically expressed in malignant pleural effusions, and is required for the
colonization of the lung. In contrast, not all antigens can meet this tripartite assessment. The
CD44 splice variants were previously shown to mediate metastasis of rat carcinoma,15 but in
our screening, even though CD44v7 was specifically and abundantly expressed, it did not
seem to be required for tumor formation (Fig. 3b). Another example is ErbB3, despite being
cancer specific (Fig. 2a) and functionally important,16,17 is expressed at a relatively low
level of 3.1 × 103 copies per cell on average. Targeting this low-abundance antigen can be
challenging and may require high-affinity antibodies. Lastly, we examined the mesenchymal
markers because tumor cells undergoing EMT are highly invasive and anchorage-
independent,8 so we expected the highly malignant cells in pleural effusions to exhibit
similar expression profile. Contrary to our hypothesis, we found that N-cad and Cad-11,
were neither abundant nor cancer specific. The tumor formation experiment also did not
suggest any requirement for Cad-11. The low expression of mesenchymal markers in our
screening indicates that tumor cells in pleural effusions are not mesenchymal but remain
predominately epithelial.
The use of pleural effusions as a source of highly malignant tumor cells can help identify
targets unique to metastasis. It is interesting to note that CD24 mediates the lung
colonization of HT29 cells without contributing significantly to tumor growth as seen in the
subcutaneous tumor growth experiment. It is known that some genes important for
metastasis do not actually have a direct effect on tumor growth, such as tumor-derived
endothelin-1.18
CD24 is a heavily glycosylated, GPI-anchored peptide expressed in naïve B cells and cancer
cells.19 Antibody against CD24 has achieved therapeutic efficacy in preclinical models,20,21
especially in the prevention of metastatic formation in the lungs. Earlier studies ascribed the
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role of CD24 in tumorigenesis and metastasis as twofold: (i) proliferation and (ii) cell
motility. CD24-siRNA knockdowns of HT29 cells showed a reduced exponential growth
and lower saturation density, with effects seen more prominently in serum-starved
conditions.20 Network analysis using gene expression arrays revealed that downregulation
of CD24 affected members in the mitogen-activated protein kinase (MAPK) pathway
downstream of Ras. Other pathways affected also included phospholipase C signaling,
vascular endothelial growth factor, hypoxia and angiogenesis.20 Another group has shown
that CD24 is regulated by Ral GTPases, which mediate cell transformation through Ras.22
Second, the involvement of CD24 in cell motility was observed when CD24-siRNA clones
of HT29 cells failed to transpass transwell assays.20 Indeed, studies have shown that CD24
promotes binding to extracellular matrix including fibronectin, laminin, collagen I and
collagen V through α3β1 and α4β1 and is important for cell spreading.23
The importance of CD24 may seem contrary to the observation that CD44+/CD24− cells
were of increased tumorigenic potential24 and potential cancer stem cells25 in breast cancer.
However, the CD44+/CD24− phenotype is not always seen in other cancer types. For
example, it is the CD44+/ CD24+ cells that take on the properties of cancer stem cells in
pancreatic cancer. Second, despite the evidence of CD24− cells being the cancer stem cells
in breast cancer, overexpression of CD24 has a poor prognosis in breast carcinomas
including increased staging, tumor grade and lymph node positivity.26 In human bladder
cancer, CD24 expression was observed in 75% of the primary tumors and 93% of the
matched metastases, suggesting a more advanced tumor staging with higher CD24
expression.21
One improvement that can be made to our study is to include a larger patient size with a
defined cancer type. In general, a sample size of 8–12 will only be powered to find effects of
a rather large size. This means that only highly overexpressed markers can be identified by
this sample size. A sample size of 8 is powered to find effects 1.5 times that of the standard
deviation of the population (see Methods). The difference seen for a few markers including
CD24 between the EpCAM+ population of the malignant effusions and the other benign
populations exceeds this magnitude (Supporting Information Table S6), and thus, our
sample size is sufficiently powered to detect the large effects. With our small sample size,
we observed considerable patient heterogeneity, indicating the need for patient stratification.
We did not limit our patients to lung cancer because effusions from rectal (LC52) and
endometrial (LC74) cancers were both tumorigenic in mice. Another limitation of our study
is that we could not obtain matched primary tumors because the resection of the primary
tumor took place years before the development of pleural effusions and was not always
performed in the same hospital. Therefore, it is unclear whether the antigens overexpressed
in pleural effusions were present in the primary tumor or in the adjacent healthy tissue.
Tumor tissue was formalin-fixed, paraffin-embedded (FFPE); membrane antigens are
sensitive to crosslinking, and not all the antibodies are developed for in FFPE slides. Future
study would involve the analysis of fresh tumor samples, and waiting 3–5 years for pleural
effusions to develop in a subset of patients. Nevertheless, an antigen expressed in normal
tissue may still be a useful cancer target when it was found in an unusual location. EpCAM,
a marker of both normal and tumor epithelia, indicates metastatic disease when present in
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pleural effusions, blood or bone marrow. Antibody against EpCAM can completely
eliminate EpCAM+ cells in the bone marrow aspirates of some patients.
Lastly, in the quantification of surface antigen abundance, we assume that all the antibodies
are equally accessible to the antigens and all antigens are labeled to saturation. It might be
more valid to verify the antigen expression by a different antibody targeting another epitope.
A more accurate quantification of surface antigen can be accomplished if the Kd of the
antibodies is known.
where yeq = fraction of saturation of surface antigens at equilibrium, [Ab] = concentration of
antibody, and Kd = affinity of the antibody. However, an estimate of Kd was not available
for each of the 35 antigens in this study.
In conclusion, we have applied a general guideline to evaluate the suitability of targets for
disseminated tumor cells: the concomitant consideration of antigen abundance, specificity
and functional importance, along with the use of tumor cells disseminated from the primary
site. CD24 is an antigen that has satisfied all three criteria, especially its functional
importance in the colonization of the lung and thus a potential relevance to metastasis. In the
future, this screening method can be extended to a greater panel of antibodies for the
discovery of targets in disseminated tumor cells.
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Figure 1. The EpCAM+ subset is tumorigenic
(a) Cells from pleural effusion samples were separated into 5 different subsets based on their
EpCAM and CD45 expression, and whether obtained from a cancer patient (malignant) or
otherwise (benign). The EpCAM+ subset was only present in the malignant effusions
whereas the EpCAM−/CD45− and CD45+ subsets were found in both the malignant and
benign effusions. (b) Malignant pleural effusions were sorted into the EpCAM+, EpCAM−/
CD45− and CD45+ subsets by flow cytometry and injected subcutaneously into NOD/SCID/
IL2γR−/− mice and monitored for tumor formation for up to a year. The table shows the ratio
Yao et al. Page 12
Int J Cancer. Author manuscript; available in PMC 2014 December 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
of the number of tumors formed to the total number of clinical samples injected. Only the
EpCAM+ subset formed tumors. (c) The pleural effusions and their corresponding xenograft
tumors were analyzed for their EpCAM and CD45 expression. The xenograft tumors were
pre-gated with HLA-ABC antibody to remove contaminating mouse cells.
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Figure 2. Surface marker expression in malignant and benign pleural effusions
(a) Each of the 5 FACS-defined subsets was stained with a panel of 35 surface markers by
flow cytometry. We determined the absolute number of receptors on the cell surface with
fluorescence calibration beads (exact values given in table S3). Shown are the average
numbers of receptors averaged across all patients from each subset. Range shown is 1×105
to 1×106 receptors/cell. Markers with * are differentially expressed in at least one subset
with p-value <0.05 (** p-value < 0.001) based on the ANOVA test. (b) For the same surface
marker expression in (a), the p-values are plotted against the absolute number of surface
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markers for the EpCAM+ subset to illustrate the point that an ideal marker is both
consistently overexpressed across different patients (p-value < 0.05) and highly expressed
(>105 receptors/cell). The dotted line separates the markers with p-value < 0.05 from those
with p-value > 0.05. Some example markers are circled in red, representing the statistically
significant markers, and in green representing the non-statistically significant markers.
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Figure 3. CD24high cells are tumorigenic
(a) To investigate which surface marker predicts tumorigenicity, we used tumor formed
from xeno-transplants of the LC52 effusion, FACS-sorted the highest and lowest 10% of
cells expressing each of the 6 markers. (b) Sorted cells were injected subcutaneously into
NOD/SCID/IL2γR−/− mice and monitored for tumor growth (n=4 per group). Red curves
represent the average tumor growth from cells expressing the highest 10% of the indicated
markers whereas the green curves represent the tumor growth from cells expressing the
lowest 10% of the markers. Error bars shown are the standard errors of the mean.
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Overexpression of CD24 and CEA correlates with faster tumor growth (*p-value < 0.05 for
each day). (c) Tumors formed from high (red bars) and low (green bars) starting populations
were analyzed for surface marker expression at the end of the tumor growth studies shown
in (b) by flow cytometry (*p-value < 0.05).
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Figure 4. CD24 is critical for tumor colonization
To investigate the functional role of CD24, we knocked down the expression of CD24 in
HT29 cells. Both the mRNA levels (a) and the surface protein expression levels (b) of CD24
were reduced by 90% in the shRNA clones. NT: non-targeted control; CD24-1: CD24
shRNA clone 1; CD24-2 shRNA clone 2. (c) HT29 cells were plated and monitored for in
vitro proliferation. The knockdown of CD24 had little effect on the in vitro proliferation of
HT29. (d) HT29 cells were injected subcutaneously and monitored for tumor formation (n=4
per group). (*p-value < 0.05). Error bars shown are the standard errors of the mean. (e)
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HT29 cells were injected intravenously and the numbers of lung nodules formed were
counted one month post injection (n=5 per group). Scale bar = 100 µm. p-value < 0.001 for
both shRNA clones. On the H&E section, black arrows indicate some examples of lung
nodules formed from HT29 cells with non-targeted shRNA control.
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